Angle Plc. Asked A.I. "parsortix vs the competition" >>>16 May 2025 14:50
AI Overview
Parsortix is a circulating tumor cell (CTC) isolation technology that competes with other methods like CellSearch and ctDNA analysis. Parsortix uses a microfluidic device to capture and collect CTCs, which can then be analyzed for RNA and protein expression. Compared to ctDNA, Parsortix provides a more complete picture of the cancer, as it allows for analysis of the entire cell.
Here's a more detailed comparison:
Parsortix vs. CellSearch:
CellSearch:
A long-standing, FDA-approved platform for CTC enumeration, particularly in prostate cancer. While it can capture CTCs, it is primarily focused on counting cells rather than detailed characterization.
Parsortix:
Offers the ability to analyze the captured CTCs for RNA and protein expression, providing a more in-depth understanding of the tumor. Parsortix can also capture a wider range of CTCs, including those that do not express EpCAM, according to a study by the Journal of Experimental & Clinical Cancer Research.
Studies:
Some studies have shown that Parsortix can capture and enumerate CTCs just as effectively as CellSearch, and may even outperform it in certain situations, especially when it comes to identifying CTCs with specific markers.
Clinical Use:
CellSearch is widely used in clinical practice for CTC enumeration, particularly in prostate cancer. Parsortix is increasingly being used for more comprehensive characterization of CTCs, as noted in a study by the National Institutes of Health (NIH) (.gov).
Parsortix vs. ctDNA:
ctDNA:
Circulating tumor DNA, which is a fraction of DNA released by cancer cells into the bloodstream. ctDNA analysis is a valuable tool for identifying mutations and other genetic changes, but it does not provide information about cell phenotype or morphology.
Parsortix:
Provides access to intact CTCs, allowing for analysis of RNA and protein expression, as well as genomic profiling. This can provide a more complete picture of the tumor than ctDNA analysis alone.
Complementary Information:
In some cases, CTCs and ctDNA can provide complementary information, revealing mutations that are exclusive to either analyte.
Overall:
Parsortix offers a versatile platform for CTC analysis, allowing for a more comprehensive understanding of the tumor than traditional methods like CellSearch.
While CellSearch remains a valuable tool for CTC enumeration, Parsortix is gaining traction for its ability to characterize CTCs at the molecular level.
ctDNA analysis and CTC analysis are often used in conjunction to provide a more complete picture of the cancer.
==========================
There you have it.
Sign In
Follow the stocks
